Inhibikase Therapeutics
IKT
12 hedge funds and large institutions have $444K invested in Inhibikase Therapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
48% more capital invested
Capital invested by funds: $299K → $444K (+$145K)
9% more funds holding
Funds holding: 11 → 12 (+1)
0.49% less ownership
Funds ownership: 3.81% → 3.32% (-0.49%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.9K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.09K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$4.41K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$144K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.95K |
| 3 |
Renaissance Technologies
New York
|
-$6.62K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3K |
| 5 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$185 |
IKT Hedge Fund Activity: Q1 2024 in Review
12 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2024, worth a combined $444K — up 48% from $299K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IKT positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $49.9K. The largest seller was Vanguard Group, cutting an estimated $144K.
- 12 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2024, up from 11 in Q4 2023.
- Funds reported $444K of Inhibikase Therapeutics stock for Q1 2024, up 48% quarter-over-quarter.
- 3 funds opened new Inhibikase Therapeutics positions in Q1 2024 and 2 closed out, a net change of +1 holder.
- The largest Inhibikase Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $49.9K added.
- The largest Inhibikase Therapeutics seller in Q1 2024 was Vanguard Group, an estimated $144K sold.
Based on aggregated 13F filings for Q1 2024.